US 11,655,307 B2
Anti-doublecortin-like kinase 1 antibodies and methods of use
Courtney W. Houchen, Edmond, OK (US); Nathaniel Weygant, Mustang, OK (US); Dongfeng Qu, Edmond, OK (US); Randal May, Oklahoma City, OK (US); Parthasarathy Chandrakesan, Edmond, OK (US); and William L. Berry, Edmond, OK (US)
Assigned to The Board of Regents of the University of Oklahoma, Norman, OK (US)
Appl. No. 16/617,074
Filed by The Board of Regents of the University of Oklahoma, Norman, OK (US)
PCT Filed May 30, 2018, PCT No. PCT/US2018/035071
§ 371(c)(1), (2) Date Nov. 26, 2019,
PCT Pub. No. WO2018/222675, PCT Pub. Date Dec. 6, 2018.
Claims priority of provisional application 62/512,372, filed on May 30, 2017.
Prior Publication US 2021/0189007 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 47/6871 (2017.08); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
 
1. An antibody or an antigen-binding portion thereof, comprising:
a heavy chain variable region comprising three complementarity determining regions, VH CDR1, VH CDR2, and VH CDR3, selected from the group consisting of (1) the amino acid sequences set forth in SEQ ID NOS: 17, 18, and 19, respectively, and (2) the amino acid sequences set forth in SEQ ID NOS: 27, 28, and 29, respectively; and
a light chain variable region comprising three complementarity determining regions, VL CDR1, VL CDR2 and VL CDR3, selected from the group consisting of (1) the amino acid sequences set forth in SEQ ID NOS: 20, 21, and 22, respectively, and (2) the amino acid sequences set forth in SEQ ID NOS: 30, 31, and 32, respectively; and
wherein the antibody or antigen-binding portion thereof specifically binds to Doublecortin-like kinase 1 (DCLK1) isoform 2 or 4.